{
    "2019-01-08": [
        [
            {
                "time": "",
                "original_text": "医药生物行业月报:结构调整下多数公司进入价值区间，创新是最确定的方向",
                "features": {
                    "keywords": [
                        "医药生物",
                        "结构调整",
                        "价值区间",
                        "创新"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医疗保健：医院收入结构调整 荐8股",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "医院收入",
                        "结构调整",
                        "荐股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗保健"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "康龙化成业务高增长率与低销售费用率相背 商誉埋雷",
                "features": {
                    "keywords": [
                        "康龙化成",
                        "高增长率",
                        "低销售费用率",
                        "商誉风险"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "2019年机构注意力转向何方，百只个股被扎堆看好或存“升”机",
                "features": {
                    "keywords": [
                        "2019年",
                        "机构注意力",
                        "个股看好",
                        "上升机会"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "2019年1月医药行业投资策略:“轻药重医”为正道,首推医疗器械板块",
                "features": {
                    "keywords": [
                        "2019年1月",
                        "医药行业",
                        "投资策略",
                        "轻药重医",
                        "医疗器械"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物",
                        "医疗器械"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}